Kamat - Figure 18
European Organization for Research and Treatment of Cancer (EORTC) 30962 study
FIG. 18: Another very important point is the timing and duration, not only the timing or the duration of the instillation of BCG, but particularly the timing of the point at which we determine that a patient has not responded to BCG or is a BCG failure.
This Figure shows data from the European Organization for Research and Treatment of Cancer (EORTC) 30962 study, which compared full-dose BCG with low-dose BCG and compared duration of 1 year vs 3 years.[19] This study highlights that BCG showed an incremental benefit with a full dose for 1 year vs low (1/3) dose for 1 year. The green and blue lines show a similar benefit for full dose for 3 years compared with full dose for 1 year. However the only statistically significant difference was between low (1/3) dose at 1 year and full dose at 3 years, and this was probably due to a sample size in which there was a clear incremental benefit with increasing duration of BCG therapy
References
Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63:462−72 http://dx.doi.org/10.1016/j.eururo.2012.10.039
